Investor Contact
For investor related questions, please email
investors@aclaristx.com

Press Releases

Press Releases

December 3, 2024
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
November 26, 2024
Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
November 18, 2024
Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline
November 18, 2024
Aclaris Therapeutics Announces $80 Million Private Placement
November 6, 2024
Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
September 17, 2024
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis
September 10, 2024
Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
August 7, 2024
Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
July 16, 2024
Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million
June 6, 2024
Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
May 7, 2024
Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
April 30, 2024
Aclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate Update
February 27, 2024
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
January 16, 2024
Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review
January 10, 2024
Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis
Load More »